anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: pharmaceutical technology. SUBSTANCE: invention relates to methods of combined processing products of apiculture and sea products, in part, to preparing the curative-prophylactic preparation "VINIBIS-C" from bee bread and ascorbic acid powder. Method involves product drying in vacuum chamber at heating to 45 C, not above, under pressure 100 mm of mercury column, not above. Before drying in vacuum chamber the preliminary drying of raw by convective method is carried out up to humidity index 15%, not above. Obtained raw is disinfected, cooled and bee bread is extracted at 0-5 C. Then product is mixed with ascorbic acid powder and ground to obtain the homogeneous powder. EFFECT: increased economy, output, safety of method, ecologically pure product with maximal level of biologically active properties. 1 dwg
Participants enrolled in this arm of the study will receive 5, 20 minutes educational training sessions designed to increase knowledge pertaining to food allergies. These sessions will occur over the period of \<2 weeks. All sessions will occur at the PIs laboratory or within the participant's home.
<P>PROBLEM TO BE SOLVED: To provide polysaccharides having new structures and physical properties derived from microbes, a method for producing the polysaccharides, and medicines, cosmetics and external skin preparations containing the polysaccharides.  <P>SOLUTION: The polysaccharides are obtained by culturing bacteria of Halomonas sp. which are marine-derived microbes and separating and purifying the cultured product. The polysaccharides essentially comprise D-galactose, D-glucuronic acid and D-mannose as structural saccharides and have a weight average molecular weight of 1,500,000 to 8,500,000 measured by gel permeation chromatography (GPC). The polysaccharides are used for a moisturizing agent, hyaluronidase inhibitor, blood coagulation inhibitor, cosmetic and external skin preparation.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The purpose of this study is to compare the bioequivalence of a test formulation of primidone tablets to an equivalent oral dose of the commercially available Mysoline® (primidone tablets) in adult subjects under fasting conditions.

Twenty-two healthy, non-smoking, non-obese male and female volunteers at least 18 years of age will be randomly assigned in a crossover fashion to receive each of two primidone dosing regimens in sequence with a 14 day washout period between dosing periods. On the morning of Day 1, after an overnight fast of at least 10 hours, subjects will receive either a single oral dose of the test formulation, primidone (1 x 50 mg tablet) or a single oral dose of the reference formulation, Mysoline® (1 x 50 mg tablet). After a 14 day washout period, on the morning of Day 15 after an overnight fast, subjects will receive the alternate regimen. Blood samples will be drawn from all participants before dosing and for 72 hours post dose at times sufficient to adequately define the pharmacokinetics of primidone. A further goal of this study is to evaluate the safety and tolerability of this regimen in healthy volunteers. Subjects will be monitored throughout the confinement portion of the study for adverse reactions to the study drugs and/or procedures. Blood pressure and heart rate will be obtained prior to dosing and at 3, 4, 6, 24 and 72 hours post-dose. All adverse events whether elicited by query, spontaneously reported or observed by clinic staff will be evaluated by the investigator and reported in the subject's case report form.
BACKGROUND: Chronic postsurgical pain (CPSP) is common following musculoskeletal and orthopedic surgeries and is associated with impairment and reduced quality of life. Several interventions have been proposed to reduce CPSP; however, there remains uncertainty regarding which, if any, are most effective. We will perform a systematic review and network meta-analysis of randomised trials to assess the comparative benefits and harms of perioperative pharmacological and psychological interventions directed at preventing chronic pain after musculoskeletal and orthopedic surgeries.
METHODS: We will search MEDLINE, Embase, PsycINFO, CINAHL, and the Cochrane Central Register of Controlled Trials from inception to present, without language restrictions. We will include randomised controlled trials that as follows: (1) enrolled adult patients undergoing musculoskeletal or orthopedic surgeries; (2) randomized them to any pharmacological or psychological interventions, or their combination directed at reducing CPSP, placebo, or usual care; and (3) assessed pain at 3 months or more after surgery. Screening for eligible trials, data extraction, and risk-of-bias assessment using revised Cochrane risk-of-bias tool (RoB 2.0) will be performed in duplicate and independently. Our main outcome of interest will be the proportion of surgical patients reporting any pain at ≥ 3 months after surgery. We will also collect data on other patient important outcomes, including pain severity, physical functioning, emotional functioning, dropout rate due to treatment-related adverse event, and overall dropout rate. We will perform a frequentist random-effects network meta-analysis to determine the relative treatment effects. When possible, the modifying effect of sex, surgery type and duration, anesthesia type, and veteran status on the effectiveness of interventions will be investigated using network meta-regression. We will use the GRADE approach to assess the certainty evidence and categorize interventions from most to least beneficial using GRADE minimally contextualised approach.
DISCUSSION: This network meta-analysis will assess the comparative effectiveness of pharmacological and psychological interventions directed at preventing CPSP after orthopedic surgery. Our findings will inform clinical decision-making and identify promising interventions for future research.
SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42023432503.
The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.

All FL3X intervention participants will receive "FL3X-Basic", which is the initial 3-month intervention that includes 4 sessions (40-60 min), supplemented with short additional contacts (via text, email, or web-based communication) as needed. Thereafter, applying principles of adaptive interventions, based on a decision rule using A1c values measured at defined intervals, participants are iteratively assigned to "FL3X-Check-in" or "FL3X-Regular", both of which continue with MI and PSST for the underlying counseling strategy. In FL3X-Check-in, participants who are doing well ("responders") will receive minimal ongoing support to reinforce successful strategies through brief monthly "touch-base" contacts. In FL3X-Regular, those who are "Regular-responders" will have a minimum of 3-4 in-person full-length sessions (40-60 min) over each 6-month interval, with additional brief contacts as needed (e.g., text, voice, or internet). FL3X participants randomized to the control group will receive usual care.
The Clinic Treatment Project focused on ethnically diverse youths aged 7-13 who were referred to community-based mental health clinics for problems involving disruptive behaviors, depression, anxiety, and any combination of these. Using a randomized block design, therapists were randomly assigned to deliver usual treatment procedures (usual care, or UC) in their clinics or evidence-based practices deployed in two forms: (a) standard manual treatment (SMT), using full treatment manuals, one at a time, exactly as they have been tested in clinical trials, and (b) modular manual treatment (MMT) in which therapists learn the component practices of the standard manuals but individualize the use of the components for each child using a guiding clinical algorithm. Unlike the SMT approach, the MMT approach allows the duration and sequencing of techniques to be individualized in an effort to fit the child's needs and allows the clinician to draw techniques from outside the target disorder domain when needed (e.g., to address noncompliance during the course of treating depression). Both SMT and MMT were supported by training and supervision procedures designed to fit providers and their clinic contexts. Assessments were carried out at pre-treatment, at post-treatment, and at 3-, 6-, 9-, 12-, 18-, and 24-month follow-ups. Assessments carried out at pre-treatment included(a) individual youth problems and disorders; (b) individual youth functioning at home and school; and (c) clinic staff beliefs and attitudes toward their work and workplace. Assessments carried out at post-treatment and follow-up only included measures of (a) youth, parent, and therapist satisfaction with treatment; (b) youth, parent and therapist views on the quality of the therapeutic relationship; and (c) treatment costs. Assessments carried out at follow-up only included (a) parent reports of any mental health service use following project treatment, and (b) therapist reports on the extent to which the treatment procedures they used in the project are continued after project termination. Analyses will address critical questions about deployment of evidence-based youth practices to clinical care settings.
Nucleic acid transporter systems for delivery of nucleic acid to a cell. The nucleic acid transporter includes a binding complex. The binding complex contains a binding molecule which noncovalently binds to the nucleic acid. The binding complex can also contain a binding molecule which is associated with a surface ligand, nuclear ligand or a lysis agent. These may be associated with the binding molecule by spacers. In addition, the transporter may include a nucleic acid with a combination of the above binding complexes or binding molecules.
Pilonidal sinus disease (PSD) is a common condition that typically affects young adults. PSD may cause significant morbidity due to its chronic nature and tendency to recur. Laser ablation has recently shown promising results in the treatment of PSD, but comparative studies are sparse. We aimed to compare laser ablation with two conventional treatment options: simple excision with direct closure and excision with flap reconstruction. This retrospective study material included patients who underwent PSD surgery in the plastic surgery department of a single academic teaching hospital. Patients were divided into three groups based on the operation technique: laser group, direct closure group, and flap group. Preoperative and postoperative data were compared between the groups including patient characteristics, residual disease, recurrent disease, complications, and re-operations. Among the 278 patients, 66 underwent laser treatment, 134 excision with direct closure, and 78 excision with flap closure. The follow-up time ranged from 15.4 ± 7.6 months in the laser group to 87.6 ± 29.3 months in the flap group. Eventless healing occurred in 67.7% of the patients in the laser group, 66.4% of the patients in the direct closure group, and 56.4% of the patients in the flap group. There was significantly more residual disease in the laser group whereas significantly more complications were found in the direct closure and flap groups. The advantages of laser treatment include fast postoperative recovery and reduced risk of complications.
PURPOSE: A method for manufacturing antibacterial hydrogel using Coptis chinensis FRANCH extract is provided to promote wound healing and to enhance antibacterial function. CONSTITUTION: Antibacterial hydrogel using Coptis chinensis FRANCH extract contains polyvinyl alcohol, succinic acid, and carboxyl methyl cellulose in a weight ratio of 10:0.5-1.9:2-4. The antibacterial hydrogel contains 0.1-60 wt% of the Coptis chinensis FRANCH extract based on total weight of polyvinyl alcohol, succinic acid, and carboxyl methyl cellulose. The extract is a hot water extract. The antibacterial hydrogel is used for wound healing and sterilizing. The antibacterial hydrogel is used as a medical material.
Vision screening during childhood is vital for the early detection and treatment of visual impairment that may significantly impact a child's development and quality of life. This nationwide cross-sectional study used data from Greenland's national electronic medical records, including 2,493 six-year-old children from July 2017 to July 2023, to evaluate the coverage rate of vision screening and the prevalence of low vision in Greenlandic schoolchildren. The participation rate in vision screening increased from 43% in 2017 to 61% in 2022, while referral rates to ophthalmologists decreased from 14% to 5%, despite a consistent prevalence of low vision. The mean prevalence of impaired vision (0.3 logMAR / ≤0.50 Snellen decimal) in the better-seeing eye at the vision screening throughout the study period was 3%. At the same time, it was 8% for the worse-seeing eyes, indicating a continuous need for ophthalmological evaluation of the Greenlandic children. This study highlights healthcare delivery challenges in Greenland's sparsely populated areas and emphasises the need for new national guidelines to optimise referral processes. Utilising other healthcare professionals, such as optometrists, for vision screenings and ensuring follow-ups are critical for improving the visual health outcomes of Greenlandic children.
At T = 0 h participants will undergo an intravenous glucose tolerance test (IVGTT, 0.33 g/kg glucose) immediately followed by a 4-hour rest period. During this time, steady-state hyperglycemia (\~10 mM) will be induced experimentally via a variable-rate intravenous infusion of 20% dextrose. At T = 5 h, participants will undertake 45 minutes of moderate-intensity (70% VO2max) bicycle ergometry. Immediately following (T = 6 h) and 1- (T = 7 h), 3- (T = 9 h), and 18- hours (T = 24 h) after exercise, participants will undergo additional IVGTTs.
Most adverse effects have been mild and transient. The following adverse reactions have been reported for immediate release metoprolol tartrate. 

Central Nervous System: Tiredness and dizziness have occurred in about 10 of 100 patients. Depression has been reported in about 5 of 100 patients. Mental confusion and short- term memory loss have been reported. Headache, somnolence, nightmares, and insomnia have also been reported. 

Cardiovascular: Shortness of breath and bradycardia have occurred in approximately 3 of 100 patients. Cold extremities; arterial insufficiency, usually of the Raynaud type; palpitations; congestive heart failure; peripheral edema; syncope; chest pain; and hypotension have been reported in about 1 of 100 patients (see CONTRAINDICATIONS, WARNINGS, and PRECAUTIONS). 

Respiratory: Wheezing (bronchospasm) and dyspnea have been reported in about 1 of 100 patients (see WARNINGS). 

Gastrointestinal: Diarrhea has occurred in about 5 of 100 patients. Nausea, dry mouth, gastric pain, constipation, flatulence, digestive tract disorders and heartburn have been reported in about 1 of 100 patients. 

Hypersensitive Reactions: Pruritus or rash have occurred in about 5 of 100 patients. Worsening of psoriasis has also been reported. 

Miscellaneous: Peyronie's disease has been reported in fewer than 1 of 100,000 patients. Musculoskeletal pain, blurred vision, decreased libido, and tinnitus have also been reported. 

There have been rare reports of reversible alopecia, agranulocytosis, and dry eyes. Discontinuation of the drug should be considered if any such reaction is not otherwise explicable. The oculomucocutaneous syndrome associated with the beta-blocker practolol has not been reported with metoprolol.
According to the present invention, disclosed is a male contraceptive tool filled with a gel-type protective material. According to the present invention, the male contraceptive tool is filled with a gel-type coating agent which has alcohol-free, preservative-free, non-toxic, non-irritating, and odorless properties while combining antibacterial, antiviral, and deodorizing active ingredients. Accordingly, when sexual intercourse is performed while the contraceptive tool is worn, antibacterial, antiviral, and deodorizing active ingredients filling the contraceptive tool are combined, and thus a gel-type coating agent having alcohol-free, preservative-free, non-toxic, non-irritating, and odorless properties is emitted to directly form a protective film in a specific region (for example, the inside of the vagina) of a female human body. Therefore, cleanliness of the specific region of the female human body is maintained. Also, infection due to bacteria or viruses related to sexual diseases such as gonorrhea or acquired immunodeficiency syndrome (AIDS) is effectively prevented during sexual intercourse. Moreover, viral sexual diseases (AIDS) and secondary infections due to human papilloma viruses or condyloma are prevented. Accordingly, a healthy sex life between a man and woman is made possible.
OBJECTIVE: to identify correlations between quality and quantity of health care resources, national economic indicators, and postoperative in-hospital mortality as reported in the EUSOS study.
METHODS: Different variables were identified from a series of publicly available database. Postoperative in-hospital mortality was identified as reported by EUSOS study. Spearman non-parametric and Coefficients of non-linear regression were calculated.
RESULTS: Quality of health care resources was strongly and negatively correlated to postoperative in-hospital mortality. Quantity of health care resources were negatively and moderately correlated to postoperative in-hospital mortality. National economic indicators were moderately and negatively correlated to postoperative in-hospital mortality. General mortality, as reported by WHO, was positively but very moderately correlated with postoperative in-hospital mortality.
CONCLUSIONS: Postoperative in-hospital mortality is strongly determined by quality of health care instead of quantity of health resources and health expenditures. We suggest that improving the quality of health care system might reduce postoperative in-hospital mortality.
A liquid drug formulation comprising clonidine and midazolam. The amount of clonidine is in the range of 5.0-50 μg/ml. The amount of midazolam is in the range of 0.5-10 mg/ml. The liquid drug formulation could be in the form of a syrup. The liquid drug formulation could be provided in a multi-use container or a single-use dispenser. Also disclosed is a method of inducing sedation in a patient using the liquid drug formulation.
This 27-week double-blind, placebo controlled treatment is designed to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in concurrent cocaine and opiate dependent patients. All subjects will receive methadone. For the treatment of cocaine dependence, subjects will receive one of 2 doses of dextroamphetamine (15 or 30mg) or placebo. After 4 weeks of treatment the dose level of dextroamphetamine is doubled (30 or 60mg). This dose is maintained for 20 weeks; during which subjects attend twice weekly visits to the clinic and receive weekly cognitive behavioral therapy. Follow up evaluations will be conducted out to 3 months post treatment. Subjects will be assisted in transferring to Houston area methadone clinics to maintain treatment for opiate dependence following treatment completion.
Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving therapy with beta-lactams. These reactions are more likely to occur in individuals with a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin hypersensitivity who have experienced severe hypersensitivity reactions when treated with another beta-lactam. Before initiating therapy with Ertapenem for injection, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, other beta-lactams and other allergens. If an allergic reaction to Ertapenem for injection occurs, discontinue the drug immediately. Serious anaphylactic reactions require immediate emergency treatment as clinically indicated.
The pulse oximetry devices were placed on subjects per the protocol. The subjects underwent gradual hypoxia and the output of the devices under test was compared to the SaO2 value as measured by a CO-Oximeter (the reference value), as outlined by ISO 80601, to ensure that the devices meet the specified performance claims.
PURPOSE:To provide the titled external agent containing an anionic water-soluble drug, by using an anionic water-soluble drug and a basic oil-soluble substance or its salt as active components. CONSTITUTION:A dermatic external agent having improved transcutaneous absorbability of an anionic water-soluble drug can be produced by compounding (A) an anionic water-soluble drug (which is solid at normal temperature and has a pKa of <=4.5: e.g. an antiepileptic agent such as valproate sodium) and (B) a basic oil-soluble substance or its salt (having one or more dissociable basic groups in the molecule and soluble in oil: e.g. alkanolamine, its salt, quaternary ammonium, its salt, alkyldiamine, its salt, etc.) at a weight ratio of 1:0.05-100, preferably 1:0.1-80. The external agent can be applied in an arbitrary form contacting with skin for a moderate period (e.g. ointment, aerosol, lotion, poultice, tape, etc.).
Preparation of a concentrate of proanthocyanidine oligomers (I) by fermenting an extract of the bark of Schinopsis lorenzii, and the use of (I) in cosmetic, pharmaceutical, agroalimentary, dietetic and chemical compositions. The extract of Schinopsis lorenzii (red quebracho, fam. Anacardiaceae) is widely used in the tanning industry and is commercially available. It may be obtained by any extraction process from the bark of the tree. This is fermented using a strain of the fungus Aspergillus niger, which process concentrates the extract into proanthocyanidine oligomers by eliminating other components, especially sugars and organic acids. It further polymerizes the monomers and dimers and de-condenses catechins. The final product (I) contains a minimum of 95% proanthocyanidine oligomers. This may be dried by spraying, evaporation, or lyophilization or used in liquid form, either encapsulated or emulsified, or absorbed onto a solid. Formulated compositions may be administered by any route.  Solid formulations preferably contain 0.01 - 15% (I), especially 0.1 - 2.5%, while capsules preferably contain 0.01 - 25% (I), especially 0.5 - 10%.